Invivyd stock falls as VYD2311 data nears
Published on 09/02/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Invivyd Inc. (US46186M1080) stock traded at $0.83 on September 2, 2026, after a 12.77 percent slide, with market capitalization at $245.54 million and volume at 8.33 million shares, according to MarketBeat. The company also said its DECLARATION and LIBERTY studies of VYD2311 are nearing completion, with top-line data expected around the end of the third quarter of 2026, as RTTNews reported on September 1, 2026.
VYD2311 now drives the story
RTTNews said Invivyd named Marc Elia chief executive officer on September 1, 2026, and kept him as chairman. That same report said the company is preparing regulatory filings that could support either traditional or accelerated approval pathways for VYD2311.
For investors, the timing matters: the next visible catalyst is tied to the end of Q3 2026, not a distant development window. The stock already reflects that pressure point, with the 52-week range at $0.53 to $3.07 and the shares still far below the higher end of that band, according to MarketBeat.
Latest quarter was mixed
MarketBeat says Invivyd reported second-quarter 2026 earnings on August 13, 2026: revenue was $14.29 million and EPS was minus $0.14, versus analyst estimates of $14.40 million and minus $0.11. That is a revenue miss of $0.11 million and an EPS miss of $0.03.
The same page lists annual sales of $53.43 million, net income of minus $52.49 million and a net margin of minus 183.90 percent, which underlines how much the market is still weighing execution against pipeline news. MarketBeat also lists a consensus rating of Hold and an average price target of $8.00.
Viral disease pipeline
Invivyd, a commercial-stage biopharmaceutical company, focuses on antibody-based solutions for infectious diseases in the United States. Its pipeline includes PEMGRADA, VYD2311 and adintrvimab, with VYD2311 now the main near-term readout.
For the stock, the near-term narrative is simple: a $0.83 share price, a $245.54 million market value and a Q2 2026 revenue base of $14.29 million against a loss of $0.14 a share.
Invivyd stock key figures
- Company: Invivyd Inc.
- ISIN: US46186M1080
- Ticker: IVVD
- Trading venue: NASDAQ
- Price (as of September 2, 2026, 1:59 PM Eastern): USD 0.83
- Market capitalization: USD 245.54 million (as of September 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Russell 3000
- Next earnings date: November 5, 2026
